AMA EMPHASIZES PRIMACY OF DOCTOR’s ROLE IN DRUG UTILIZATION REVIEW: REVIEW MUST FOCUS ON QUALITY OF CARE; AMA MID-YEAR MEETING TO REVIEW BOARD REPORT
The American Medical Association can support drug utilization review programs providing that physicians are "actively involved in the development, implementation and maintenance of the DUR programs," according to a draft report to be considered by the association's House of Delegates. "Often it is difficult to define a precise range of accepted medical practice for any given prescribing issue, such as the appropriateness of a specific drug for an illness," the committee report says. "Thus, it is essential that prescribing standards for DUR be developed by physicians and that they be based on the peer-reviewed medical literature and the experiences of physicians with expertise in drug therapy." Developed by the association's Board of Trustees, the report will be considered at AMA's Interim Meeting Dec. 2-5 in Orlando, Fla. The AMA report also states that in an acceptable DUR program, "primary emphasis is placed on high quality patient care through improved prescribing by physicians, dispensing by pharmacists, and medication compliance by patients." In addition, "focused professional education is emphasized as the primary intervention strategy." AMA's concern with DUR was heightened when Congress passed the Medicare Catastrophic Care Act in 1988, which was repealed in 1989. During discussions about the program with the Health Care Financing Administration, AMA urged that Medicare DUR not be run by "drug bill processors" who "lacked the knowledge of what constitutes appropriate prescribing practices." DUR is again in the spotlight with the enactment of the Medicaid drug prudent purchasing law (see preceding story). Drug utilization review programs are defined in the report as formal mechanisms for assessing data on drug use against set standards. The object of the programs is to correct patterns of drug use that are inconsistent with the standards. The report recommends that AMA ** oppose DUR programs that "focus only on cost containment and prevent physicians form prescribing the most appropriate drugs for individual patients"; ** "interact with appropriate pharmacy organizations to develop guidelines for prospective point-of-sale DUR that will decrease the incidence of adverse events from drug therapy"; and ** "recognize the right of government and private third-party payers to include in DUR programs a component that addresses fraud and abuse, but reaffirms the right of physicians, who are so accused, to due process."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth